Biopharmaceutical company SAB Biotherapeutics (SAB) on Saturday provided an update of the interim analysis of the defined safety and efficacy data of SAB-185 in the phase 2 part of the ACTIV-2 study, following an independent Data Safety Monitoring Board (DSMB ) review.
The company said SAB-185 is a fully human, targeted, broadly neutralizing polyclonal antibody drug candidate for the treatment of non-hospitalised patients with mild to moderate COVID-19.
SAB-185 is being tested in the ACTIV-2 study, which is funded and carried out by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the NIH (National Institutes of Health, USA) - in collaboration with the AIDS Clinical Trials Group.
According to the company, the lower and higher doses of SAB-185 tested in phase 2 met the pre-defined efficacy target for transition to phase 3 and were shown to be safe in the interim analysis. The NIAID and SAB researchers are currently in the process of determining the preferred dose for the Phase 3 trial. SAB-185 is being transferred to phase 3 study upon meeting defined promotion criteria.
SAB added that the Phase 3 portion of the ACTIV-2 study is a randomized, open-label, active comparator-controlled, adaptive platform study to evaluate the clinical safety and efficacy of SAB-185 compared to active control treatment with a monoclonal antibody in patients with mild to moderate COVID-19, who have a higher risk of hospitalisation. The primary outcome measured the safety and non-inferiority to prevention of a composite endpoint defined as either hospitalisation or death from any cause by study day 28.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer